AmerisourceBergen May Become CAP Vendor, But Oncology Is A Tough Sell
AmerisourceBergen is weighing whether to bid to become a vendor for Medicare Part B's competitive acquisition program (CAP)
You may also be interested in...
Bowing to a major demand of both vendors and physicians, the Centers for Medicare & Medicaid Services will exempt Part B competitive acquisition program drug prices from average sales price calculations, at least for the first three years of the CAP
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials